<DOC>
<DOCNO>EP-0629617</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Heteroatom-bearing ligands and metal complexes thereof
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C25138	C07F1700	C07D23300	C07D23391	C07F1300	A61K5100	C07D24914	A61P4300	C07F1700	C07D30700	C07D23395	C07D24900	C07D30771	C07F1300	A61K5100	A61P4300	C07D23354	A61K5102	A61K5104	C07C25100	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07F	C07D	C07D	C07F	A61K	C07D	A61P	C07F	C07D	C07D	C07D	C07D	C07F	A61K	A61P	C07D	A61K	A61K	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C251	C07F17	C07D233	C07D233	C07F13	A61K51	C07D249	A61P43	C07F17	C07D307	C07D233	C07D249	C07D307	C07F13	A61K51	A61P43	C07D233	A61K51	A61K51	C07C251	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel compounds containing a heteroatom-bearing 
bridge and novel complexes of these 

compounds with metals. The novel compounds and 
complexes are useful as diagnostics and therapeutics. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BRACCO INT BV
</APPLICANT-NAME>
<APPLICANT-NAME>
BRACCO INTERNATIONAL B.V.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
RAJU NATARAJAN
</INVENTOR-NAME>
<INVENTOR-NAME>
RAMALINGAM KONDAREDDIAR
</INVENTOR-NAME>
<INVENTOR-NAME>
RAJU, NATARAJAN
</INVENTOR-NAME>
<INVENTOR-NAME>
RAMALINGAM, KONDAREDDIAR
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention relates to novel compounds containing a heteroatom-bearing bridge, and to novel complexes of these compounds with metals. The novel compounds and complexes of the present invention find utility as diagnostics and therapeutics.Metal complexes, such as those containing radioactive metals, are finding increasing use as diagnostic and therapeutic agents. Of particular interest are those complexes containing bioactive moieties capable of being selectively taken up at a desired site to facilitate evaluation or treatment of a subject.The present invention addresses the need in the art for such complexes, including the ligands from which they are prepared, particularly such complexes containing hypoxia-localizing moieties.The present invention provides novel compounds, also referred to herein as ligands, of the following formula:
in which Y1 is -NR0- or -O- wherein R0 is H or C1-C12 alkyl, and each of the groups R and R* are, independetly: (i) R2; (ii) halogen; (iii) -OR2; (iv) -CO-OR2; (v) -CON(R2)2; (vi) -N(R2)2; (vii) -alkylene-CO-OR2; (viii) -alkylene-CO-N(R2)2; (ix) -alkylene-N(R2)2; (x) -arylene-CO-OR2; (xi) -arylene -CO-N(R2)2; (xii) -arylene-N(R2)2; (xiii) -acyl; (xiv) -acyloxy; (xv) -heterocyclo; (xvi) hydroxyalkyl; (xvii) -SO2-R2; (xviii) -alkyl-SO2-R2; (xix) -(A)p-R3, where A is a linker selected from -O-; -S-; -CO-; -CS-; -NH- ; -NR5-; -HC=N-; -CR5=N-; -heterocyclo-; -alkylenes- and -alkenylenes- such as -CH2-, -CHR5-, -CR5R6-, -CH=CH-, -CHCR5-, -CR5=CR6-, in which R5 and R6 are indenpendently alkyl-, alkenyl-, alkoxy-, aryl-, 5- or 6-membered N- or O-containing heterocycles, halogen-, HO- or hydroxyalkyl; -alkynylenes- such as -C≡C-; -cycloalkylene-; -cycloalkenylene-; -arylene- such as unsubstituted or HO-substituted phenylene; -arylalkylenes-; -hydroxyalkylenes-, -aminoalkylenes-; -amidoalkylenes-; and -alkylamino-alkylenes-; p is 0 to 20, and R3 is a bioactive group selected from amphetamines, barbiturates, sulfonamides, monoamine oxidase substrates and inhibitors, hormones, enzymes, lipids, ligands for cell membrane receptors, antihypertensives, neurotransmitters, aminoacids, oligo-peptides, radiosensitizers, steroids, such as estrogen and estradiol, mono- and polyclonal antibodies as well as the fragments thereof, sugars such as glucose derivatives, fatty acids, substrates for muscarine receptors such as 3-quinuclidinyl benzilate, substrates for dopamine receptors such as spiperone, biotin, chemotactic peptides, substrates for benzodiazepine receptors, and hypoxia
</DESCRIPTION>
<CLAIMS>
A compound of the following formula:


in which Y
1
 is -NR
0
- or -O- wherein R
0
 is H or C
1
-C
12
 alkyl, and each of the groups R and R* are, independetly:

(i) R
2
; (ii) halogen; (iii) -OR
2
; (iv) -CO-OR
2
; (v) -CON(R
2
)
2
; (vi) -N(R
2
)
2
; (vii) -alkylene-CO-OR
2
; (viii) -alkylene-CO-N (R
2
)
2
 ; (ix) -alkylene-N (R
2
)
2
 ; (x) -arylene-CO-OR
2
; (xi) -arylene-CO-N (R
2
)
2
; (xii) -arylene-N(R
2
)
2
; (xiii) -acyl; (xiv) -acyloxy; (xv) -heterocyclo; (xvi) hydroxyalkyl; (xvii) -SO
2
-R
2
; (xviii) -alkyl-SO
2
-R
2
; (xix) -(A)
p
-R
3
, where A is a linker selected from -O-; -S-; -CO-; -CS-; -NH-; -NR
5
-; -HC=N-; -CR
5
=N-; -heterocyclo-; -alkylenes- and -alkenylenes- such as -CH
2
-, -CHR
5
-, -CR
5
R
6
-, -CH=CH-, -CHCR
5
-, -CR
5
=CR
6
-, in which R
5
 and R
6
 are indenpendently alkyl-, alkenyl-, alkoxy-, aryl-, 5- or 6-membered N- or O-containing heterocycles, halogen-, HO- or hydroxyalkyl; -alkynylenes- such as -C≡C-; -cycloalkylene-; -cycloalkenylene-; -arylene- such as unsubstituted or HO-substituted phenylene; -arylalkylenes-; -hydroxyalkylenes-, -aminoalkylenes-; -amidoalkylenes-; and -alkylamino-alkylenes-; p is 0 to 20, and R
3
 is a bioactive group selected from amphetamines, barbiturates, sulfonamides, monoamine oxidase substrates and inhibitors, hormones, enzymes, lipids, ligands for cell membrane receptors, antihypertensives, neurotransmitters, aminoacids, oligo-peptides, radiosensitizers, steroids, such as estrogen and estradiol, mono- and polyclonal antibodies as well as the fragments
 thereof, sugars such as glucose derivatives, fatty acids, substrates for muscarine receptors such as 3-quinuclidinyl benzilate, substrates for dopamine receptors such as spiperone, biotin, chemotactic peptides, substrates for benzodiazepine receptors, and hypoxia localizing moieties of structures


wherein D is a group of atoms that forms, together with the N or O atoms to which it is bound, a 5- or 6-membered ring, n is the total number of substitution positions available on the ring, and one or more of the R
7
 groups are independently H, halogen, alkyl, aryl, alkoxy, OH, hydroxyalkyl, hydroxyalkoxy, alkenyl, arylalkyl, alkylamido, arylalkylamido, aklylamino, and (alkylamino)-alkyl; or

(xx) two R groups, or one R and one R*, taken together with the one or more atoms to which they are bound, form a saturated or unsaturated spiro or fused, carbocyclic or heterocyclic ring which may or not be substituted with one or more of the groups (i) to (xix), with the proviso that an R bearing C atom is not directly linked to more than one heteroatom;

and R
2
 is independently H, alkyl, alkenyl, alkynyl, or aryl.
A compound of claim 1 wherein, when said compound contains a group (xx), said group contains two R groups taken together with the one or more atoms to which they are bonded, to form a saturated or unsaturated, spiro
 or fused, carbocyclic or heterocyclic ring which may be unsubstituted or substituted by one or more groups selected from the groups (i) to (xix).
A compound of claim 1 having the following formula Ia':


wherein Z
1
 and Z
2
 are R
*
 groups and Z
3
 is an R group, and further where one, two or all three of Z
1
, Z
2
 and Z
3
 are - (A)
p
-R
3
 groups.
A compound of claim 3 where Y
1
 is -O-.
A compound of claim 3 where R
3
 is a hypoxia-localizing moiety.
A compound of claim 5 where the R or R* groups which are not -(A)
p
-R
3
 are hydrogen or alkyl groups.
A compound of claim 5 where R
3
 is a nitroimidazole or nitrofuran group.
A compound of claim 1 which is selected from the group consisting of:

3,3,5,9,9-pentamethyl-4,5,8-triazaundecane-2,10-dione dioxime;
11-(2-nitro-1H-imidazol-1-yl)-3,3,5,9,9-pentamethyl-4,5,8-triazaundecane-2,10-dione dioxime;
12-(2-nitro-1H-imidazol-1-yl)-3,3,5,9,9-pentamethyl-4,5,8-triazadodecane-2,10-dione dioxime;
1-(2-nitro-1H-imidazol-1-yl)-3,3,5,9,9-pentamethyl-4,5,8-triazaundecane-2,10-dione dioxime;
1-(2-nitro-1H-imidazol-1-yl)-4,4,6,10,10-pentamethyl-5,6,9-triazadodecane-3,11-dione dioxime;
3,3,9,9-tetramethyl-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
11-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
1-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
12-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-7-oxa-4,8-diaza-2,10-dodecanedione dioxime;
12-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-5-oxa-4,8-diaza-2,10-dodecanedione dioxime;
1,13-bis(2-nitro-1H-imidazol-1-yl)-4,4,10,10-tetramethyl-6-oxa-5,9-diaza-3,11-tridecanedione dioxime;
1-[[2-nitro-1H-imidazol-1-yl)acetyl]amino]
-3,3,9,9-tetramethyl-5-oxa-4,8-diaza-2,10-undecanedione dioxime;
1-[2-hydroxy-3-(2-nitro-1H-imidazol-1-yl)propoxy]-3,3,9,9-tetramethyl-5-oxa-4,8-diaza-2,10-undecanedione dioxime;
1-hydroxy-3,3,9,9-tetramethyl-12-(2-nitro-1H-imidazol-1-yl)-7-oxa-4,8-diazadodecane-2,10-dione dioxime;
3,3,9,9-tetramethyl-6-[(2-nitro-1H-imidazol-1-yl)methyl]-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
4,4,10,10-tetramethyl-1,13-bis(2-nitro-1H-imidazol-1-yl)-7-[(2-nitro-1H-imidazol-1-yl)methyl]-6-oxa-5,9-diazatridecane-3,11-dione dioxime; 1,13-bis(2-nitro-1H-imidazol-1-yl)-4,4,10,10-tetramethyl-6-oxa-7-(hydroxymethyl)-5,9-diaza-3,11-dodecanedione dioxime;
12-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-6-(hydroxymethyl)-7-oxa-4,8-diaza-2,10-dodecanedione dioxime;
3,3,9,9-tetramethyl-6-[[3-(2-nitro-1H-imidazol-1-yl)propoxy]methyl]
-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
1-ethoxy-3,3,9,9-tetramethyl-12-(2-nitro-1H-imidazol-1-yl)-6- [(2-nitroimidazol-1-yl)methyl]-7-oxa-4,8-diazadodecane-2,10-dione dioxime;
3, 3, 9, 9-tetramethyl-1-ethoxy-6-[(2-nitro-1H-imidazol-1-yl)methyl]-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
4,4,10,10-tetramethyl-7-[(2-nitro-1H-imidazol-1-yl)methyl]-6-oxa-5,9-diazatridecane-3,11-dione dioxime;
4,4,10,10-tetramethyl-7-[(2-nitro-1H-imidazol-1-yl)methyl]-8-oxa-5,9-diazapentadecane-3,11-dione dioxime;
5,5,11,11-tetramethyl-1-(5-nitro-2-furyl)-2,9-dioxa-6,10-diazatetradecane-4,12-dione dioxime;
5,5,11,11-tetramethyl-1-(5-nitro-2-furyl)-2,7-dioxa-6,10-diazatetradecane-4,12-dione dioxime;
3,3,9,9-tetramethyl-1-[[(5-nitro-2-furyl)carbonyl]amino]
-5-oxa-4,8-diazaundecane-2,10-dione dioxime; and
3,3,6,9,9-pentamethyl-5-oxa-4,8-diaza-4,8-diazaundecane-2,10-dione dioxime.
A compound of claim 1 which is:

(R)-3,3,9,9-tetramethyl-6-[(2-nitro-1H-imidazol-1-yl)methyl]-5-oxa-4,8-diazaundecane-2,10-dione dioxime;

or
(S)-3,3,9,9-tetramethyl-6-[(2-nitro-1H-imidazol-1-yl)methyl]-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
A complex comprising a compound of claim 1 complexed with a metal.
A complex of claim 10 having the following formula:


where the R and R* groups are as defined above; and where M is a radioactive or non-radioactive metal which may optionally have other co-ligand(s) W
1
 and/or W
2
 in the unfilled coordination sites thereof.
A complex of claim 11 where the metal is technetium or rhenium.
A complex of claim 11 having the following structure:


where M
1
 is technetium and wherein at least one R or R* group is -(A)
p
-R
3
.
A complex of claim 10 wherein technetium is complexed with a compound selected from the group consisting of:
3,3,5,9,9-pentamethyl-4,5,8-triazaundecane-2,10-dione dioxime;
11-(2-nitro-1H-imidazol-1-yl)-3,3,5,9,9-pentamethyl-4,5,8-triazaundecane-2,10-dione dioxime;
12-(2-nitro-1H-imidazol-1-yl)-3,3,5,9,9-pentamethyl-4,5,8-triazadodecane-2,10-dione dioxime;
1-(2-nitro-1H-imidazol-1-yl)-3,3,5,9,9-pentamethyl-4,5,8-triazaundecane-2,10-dione dioxime;
1-(2-nitro-1H-imidazol-1-yl)-4,4,6,10,10-pentamethyl-5,6,9-triazadodecane-3,11-dione dioxime;
3,3,9,9-tetramethyl-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
11-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
1-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
12-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-7-oxa-4,8-diaza-2,10-dodecanedione dioxime;
12-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-5-oxa-4,8-diaza-2,10-dodecanedione dioxime;
1,13-bis(2-nitro-1H-imidazol-1-yl)-4,4,10,10-tetramethyl-6-oxa-5,9-diaza-3,11-tridecanedione dioxime;
1-[[2-nitro-1H-imidazol-1-yl)acetyl]amino]
 -3,3,9,9-tetramethyl-5-oxa-4,8-diaza-2,10-undecanedione dioxime;
1-[2-hydroxy-3-(2-nitro-1H-imidazol-1-yl)propoxy]-3,3,9,9-tetramethyl-5-oxa-4,8-diaza-2,10-undecanedione dioxime;
1-hydroxy-3,3,9,9-tetramethyl-12-12-nitro-1H-imidazol-1-yl)-7-oxa-4,8-diazadodecane-2,10-dione dioxime;
3,3,9,9-tetramethyl-6-[(2-nitro-1H-imidazol-1-yl)methyl]-5-oxa-4,8-diazaundecane-2,10-dionedioxime;
4,4,10,10-tetramethyl-1,13-bis(2-nitro-1H-imidazol-1-yl)-7-[(2-nitro-1H-imidazol-1-yl)methyl]-6-oxa-5,9-diazatridecane-3,11-dione dioxime;
1,13-bis(2-nitro-1H-imidazol-1-yl)-4,4,10,10-tetramethyl-6-oxa-7-(hydroxymethyl)-5,9-diaza-3,11-dodecanedione dioxime;
12-(2-nitro-1H-imidazol-1-yl)-3,3,9,9-tetramethyl-6-(hydroxymethyl)-7-oxa-4,8-diaza-2,10-dodecanedione dioxime;
3,3,9,9-tetramethyl-6-[[3-(2-nitro-1H-imidazol-1-yl)propoxy]methyl]
-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
1-ethoxy-3,3,9,9-tetramethyl-12-(2-nitro-1H-imidazol-1-yl)-6-[(2-nitroimidazol-1-yl)methyl]-7-oxa-4,8-diazadodecane-2,10-dione dioxime;
3,3,9,9-tetramethyl-1-ethoxy-6-[(2-nitro-1H-imidazol-1-yl)methyl]-5-oxa-4,8-diazaundecane-2,10-dione dioxime;
4,4,10,10-tetramethyl-7-[(2-nitro-1H-imidazol-1-yl)methyl]-6-oxa-5,9-diazatridecane-3,11-dione dioxime;
4,4,10,10-tetramethyl-7-[(2-nitro-1H-imidazol-1-yl)methyl]-8-oxa-5,9-diazapentadecane-3,11-dione dioxime;
5,5,11,11-tetramethyl-1-(5-nitro-2-furyl)-2,9-dioxa-6,10-diazatetradecane-4,12-dione dioxime;
5,5,11,11-tetramethyl-1-(5-nitro-2-furyl)-2,7-dioxa-6,10-diazatetradecane-4,12-dione dioxime;
3,3,9,9-tetramethyl-1-[[(5-nitro-2-furyl)carbonyl]amino]
-5-oxa-4,8-diazaundecane-2,10-dione dioxime; and
3,3,6,9,9-pentamethyl-5-oxa-4,8-diaza-4,8-diazaundecane-2,10-dione dioxime.
A complex of claim 14 which is:

Oxo[(R)-6-(2-nitro-1H-imidazol-1-yl)methyl]-3,3,9,9-tetramethyl-5-oxa-4,8-diaza-2,10-undecanedione dioximato]
 (3-) -N,N',N",N'''] technetium-
99m
Tc (V) ; or
Oxo[(S)-6-(2-nitro-1H-imidazol-1-yl)methyl]-3,3,9,9-tetramethyl-5-oxa-4,8-diaza-2,10-undecanedione dioximato]
 (3-)-N,N',N",N''']technetium-
99m
Tc(V).
A complex as defined in claim 10 for use as a diagnostic.
The complex of claim 16 where the metal of said complex is technetium.
Use of a complex as defined in claim 10 for the preparation of a diagnostic composition for imaging hypoxic tissue.
A complex as defined in claim 10 for use as a pharmaceutically active ingredient.
The complex of claim 19 where the metal of said complex is rhenium.
A kit comprising a compound of claim 1 and a pharmaceutically acceptable reducing agent.
The kit of claim 21 wherein said kit comprises a single vial containing said compound of claim 1 and said reducing agent.
The kit of claim 21 wherein said kit comprises first and second vials, where said first vial contains said compound of claim 1 and said second vial contains said reducing agent.
A method for the stereoselective preparation of a compound of claim 9, comprising the steps of:

(i) reacting (S)-(+)-epichlorohydrin or (R)-(-)-epichlorohydrin with phthalimide to form a stereoisomer of 1-chloro-3-phthalimido-2-propanol;
(ii) contacting the product of (i) with an epoxide ring-forming agent to obtain a stereoisomer of N-(2,3-epoxypropyl)phthalimide;
(iii) contacting the product of (ii) with a base and 2-nitroimidazole to obtain a stereoisomer of 2-[2-hydroxy-2-(nitro-1H-imidazol-1-yl)ethyl]-1H-isoindole-1,3(2H)-dione;
(iv) contacting the product of (iii) with hydrazine, followed by a base and ditertiarybutyl dicarbonate, to
 obtain a stereoisomer of α-[(t-Boc-amino)methyl]-2-nitro-1H-imidazole-1-ethanol;
(v) contacting the product of (iv) with N-hydroxyphthalimide, triphenylphosphine and diethylazodicarboxylate to obtain a stereoisomer of 2-[1-[(t-Boc-amino)methyl]-2-(2-nitro-1H-imidazol-1-yl)ethoxy]
1H-isoindole-1,3(2H)-dione;
(vi) contacting the product of (v) with hydrazine to obtain a stereoisomer of 1-[2-aminooxy)-3-(t-Boc-amino)propyl]-2-nitro-1H-imidazole ;
(vii) deprotecting the product of (vi) to obtain a stereoisomer of 1-[3-amino-2-(aminooxy)propyl]-2-nitro-1H-imidazole; and
(viii) contacting the product of (vii) with 3-chloro-3-methyl-2-nitrosobutane in the presence of a tertiary amine

to obtain said compound of claim 9.
</CLAIMS>
</TEXT>
</DOC>
